Recruiting × INDUSTRY × Carcinoma, Non-Small-Cell Lung × Clear all CEMI-LUNG
Recruiting
500 enrolled
INTerpath-002
Phase 3 Recruiting
868 enrolled
A Phase 1/2 Study of VS-7375 in Patients With KRAS G12D-Mutated Solid Tumors
Phase 1/2 Recruiting
295 enrolled
A First in Human Study of ALX2004 With Advanced or Metastatic Selected Solid Tumors
Phase 1 Recruiting
170 enrolled
CHOICE
Recruiting
590 enrolled
Phase 1/2 Trial of S241656 in Selected RAS/MAPK Mutation- Positive Malignancies
Phase 1/2 Recruiting
554 enrolled
A Study of [225Ac]Ac-AKY-1189 in Patients With Solid Tumors
Phase 1 Recruiting
150 enrolled
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Phase 3 Recruiting
680 enrolled
Phase I Study of [177Lu]Lu-DFC413 in Patients With Solid Tumors
Phase 1 Recruiting
180 enrolled
Dabrafenib and/or Trametinib Rollover Study
Phase 4 Recruiting
100 enrolled
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
Phase 1 Recruiting
1,006 enrolled
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
Phase 1 Recruiting
714 enrolled
THIO Sequenced With Cemiplimab in Advanced NSCLC
Phase 2 Recruiting
227 enrolled
KRAScendo 170
Phase 1/2 Recruiting
320 enrolled
A Study Evaluating Sotorasib Platinum Doublet Combination Versus Pembrolizumab Platinum Doublet Combination as a Front-Line Therapy in Participants With Stage IV or Advanced Stage IIIB/C Nonsquamous Non-Small Cell Lung Cancers (CodeBreaK 202)
Phase 3 Recruiting
750 enrolled
SUNRAY-01
Phase 3 Recruiting
1,264 enrolled
A Study of SGN-CEACAM5C in Adults With Advanced Solid Tumors
Phase 1 Recruiting
914 enrolled
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Phase 1 Recruiting
85 enrolled
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
124 enrolled
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Phase 1 Recruiting
330 enrolled
NEXUS-01
Phase 1 Recruiting
420 enrolled
A Study of LY4050784 in Participants With Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
340 enrolled
MOONRAY-01
Phase 1 Recruiting
630 enrolled
INTerpath-009
Phase 3 Recruiting
680 enrolled
Be6A Lung-02
Phase 3 Recruiting
714 enrolled
A Study of BL-B01D1 in Combination With Osimertinib Versus Osimertinib as First-Line Treatment in Patients With EGFR-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer(PANKU-Lung04)
Phase 3 Recruiting
720 enrolled
SUNRAY-02
Phase 3 Recruiting
700 enrolled
KANDLELIT-007
Phase 3 Recruiting
675 enrolled
Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Phase 3 Recruiting
1,410 enrolled
Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
Phase 1/2 Recruiting
162 enrolled
Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer
Phase 2 Recruiting
35 enrolled
RC148 Plus Platinum-Based Chemotherapy vs Tislelizumab Plus Platinum-Based Chemotherapy for First-Line Squamous Non-Small Cell Lung Cancer (sqNSCLC)
Phase 3 Recruiting
574 enrolled
KANDLELIT-013
Phase 3 Recruiting
400 enrolled
A Study to Investigate the Safety, Pharmacokinetics, and Preliminary Efficacy of IDE574 Therapy in Adult Participants With Advanced Solid Tumors
Phase 1/2 Recruiting
160 enrolled
MK-3475-U01
Recruiting
1,065 enrolled
A Clinical Study of the Safety and Effectiveness of an Investigational Cell Therapy Given With and Without an Investigational RNA-based Vaccine in Patients With Organ Tumors
Phase 1 Recruiting
214 enrolled
A Study Evaluating the Safety and Efficacy of AUR107 in Patients With Relapsed Advanced Malignancies (SHAKTI-1)
Phase 1 Recruiting
50 enrolled
TroFuse-019
Phase 3 Recruiting
780 enrolled
A First-in-human Study to Learn How Safe BAY 3713372 is and How it Works in Participants With MTAP-deleted Solid Tumors
Phase 1/2 Recruiting
370 enrolled
A Study of LY4175408 in Participants With Advanced Cancer
Phase 1 Recruiting
240 enrolled
A Study of PHN-012 in Patients With Advanced Solid Tumors
Phase 1 Recruiting
165 enrolled
IMFINZI-subQ
Phase 1 Recruiting
40 enrolled
KAT6
Phase 2 Recruiting
320 enrolled
LIMITLESS
Phase 3 Recruiting
30 enrolled
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
Phase 2/3 Recruiting
596 enrolled
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
Phase 3 Recruiting
480 enrolled
A Study of KIVU-107 in Participants With Locally Advanced or Metastatic Solid Tumors
Phase 1 Recruiting
76 enrolled
Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer
Phase 2 Recruiting
170 enrolled
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Phase 1 Recruiting
45 enrolled
A Phase Ib/II Study of an Anti-HER3 Antibody, HMBD-001, With Cetuximab +/- Docetaxel in Advanced Squamous Cell Cancers
Phase 1/2 Recruiting
398 enrolled